Linked Life Data

20739209

Source:http://linkedlifedata.com/resource/pubmed/id/20739209

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6-7
pubmed:dateCreated
2010-9-27
pubmed:abstractText
Most of patients with hepatocellular carcinoma (HCC) cannot benefit from surgical therapies. Among nonsurgical options, only radiofrequency can challenge surgery for small size tumours. Conformal radiotherapy is likely highly efficient on solitary tumours, but controlled studies are warranted to conclude. Other options are purely palliative. Transarterial hepatic chemoembolization is the goal-standard for multifocal hepatocellular carcinoma and sorafenib for hepatocellular carcinoma with portal vein invasion, leading to modest but significant benefit on survival rates. Yttrium-90 radioembolization is under evaluation through controlled studies, and could be of major interest for multifocal hepatocellular carcinoma with or without portal venous invasion.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1769-6658
pubmed:author
pubmed:copyrightInfo
Copyright © 2010. Published by Elsevier SAS.
pubmed:issnType
Electronic
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
469-73
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Nonsurgical management of hepatocellular carcinoma].
pubmed:affiliation
Service d'Hépato-Gastroentérologie, Hôpital de l'Hôtel-Dieu, 1, Place de l'Hôpital, 69002 Lyon, France. philippe.merle@inserm.fr
pubmed:publicationType
Journal Article, English Abstract, Review